Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.

Norman BP, Davison AS, Ross GA, Milan AM, Hughes AT, Sutherland H, Jarvis JC, Roberts NB, Gallagher JA, Ranganath LR.

Clin Chem. 2019 Apr;65(4):530-539. doi: 10.1373/clinchem.2018.295345. Epub 2019 Feb 19.

PMID:
30782595
2.

Evaluation of the Mitra microsampling device for use with key urinary metabolites in patients with Alkaptonuria.

Taylor JM, Hughes AT, Milan AM, Rudge J, Davison AS, Ranganath LR.

Bioanalysis. 2018 Dec;10(23):1919-1932. doi: 10.4155/bio-2018-0193. Epub 2018 Nov 6.

PMID:
30412682
3.

Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone.

Griffin R, Psarelli EE, Cox TF, Khedr M, Milan AM, Davison AS, Hughes AT, Usher JL, Taylor S, Loftus N, Daroszewska A, West E, Jones A, Briggs M, Fisher M, McCormick M, Judd S, Vinjamuri S, Sireau N, Dillon JP, Devine JM, Hughes G, Harrold J, Barton GJ, Jarvis JC, Gallagher JA, Ranganath LR.

Data Brief. 2018 Sep 12;20:1620-1628. doi: 10.1016/j.dib.2018.09.021. eCollection 2018 Oct.

4.

Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.

Ranganath LR, Khedr M, Milan AM, Davison AS, Hughes AT, Usher JL, Taylor S, Loftus N, Daroszewska A, West E, Jones A, Briggs M, Fisher M, McCormick M, Judd S, Vinjamuri S, Griffin R, Psarelli EE, Cox TF, Sireau N, Dillon JP, Devine JM, Hughes G, Harrold J, Barton GJ, Jarvis JC, Gallagher JA.

Mol Genet Metab. 2018 Sep;125(1-2):127-134. doi: 10.1016/j.ymgme.2018.07.011. Epub 2018 Jul 24.

PMID:
30055994
5.

Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.

Davison AS, Harrold JA, Hughes G, Norman BP, Devine J, Usher J, Hughes AT, Khedr M, Gallagher JA, Milan AM, J C G H, Ranganath LR.

Mol Genet Metab. 2018 Sep;125(1-2):135-143. doi: 10.1016/j.ymgme.2018.07.008. Epub 2018 Jul 19.

PMID:
30049652
6.

Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.

Davison AS, Norman BP, Smith EA, Devine J, Usher J, Hughes AT, Khedr M, Milan AM, Gallagher JA, Ranganath LR.

JIMD Rep. 2018;41:109-117. doi: 10.1007/8904_2018_109. Epub 2018 May 13.

7.

Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment.

Davison AS, Norman B, Milan AM, Hughes AT, Khedr M, Rovensky J, Gallagher JA, Ranganath LR.

JIMD Rep. 2018;41:1-10. doi: 10.1007/8904_2017_72. Epub 2017 Nov 17.

8.

Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.

Khedr M, Judd S, Briggs MC, Hughes AT, Milan AM, Stewart RMK, Lock EA, Gallagher JA, Ranganath LR.

JIMD Rep. 2018;40:31-37. doi: 10.1007/8904_2017_62. Epub 2017 Sep 24.

9.

Delayed Cryptochrome Degradation Asymmetrically Alters the Daily Rhythm in Suprachiasmatic Clock Neuron Excitability.

Wegner S, Belle MDC, Hughes ATL, Diekman CO, Piggins HD.

J Neurosci. 2017 Aug 16;37(33):7824-7836. doi: 10.1523/JNEUROSCI.0691-17.2017. Epub 2017 Jul 11.

10.

Circadian Disruptions in the Myshkin Mouse Model of Mania Are Independent of Deficits in Suprachiasmatic Molecular Clock Function.

Timothy JWS, Klas N, Sanghani HR, Al-Mansouri T, Hughes ATL, Kirshenbaum GS, Brienza V, Belle MDC, Ralph MR, Clapcote SJ, Piggins HD.

Biol Psychiatry. 2018 Dec 1;84(11):827-837. doi: 10.1016/j.biopsych.2017.04.018. Epub 2017 May 20.

11.

The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.

Milan AM, Hughes AT, Davison AS, Devine J, Usher J, Curtis S, Khedr M, Gallagher JA, Ranganath LR.

Ann Clin Biochem. 2017 May;54(3):323-330. doi: 10.1177/0004563217691065. Epub 2017 Mar 16.

PMID:
28081634
12.

Constant light enhances synchrony among circadian clock cells and promotes behavioral rhythms in VPAC2-signaling deficient mice.

Hughes AT, Croft CL, Samuels RE, Myung J, Takumi T, Piggins HD.

Sci Rep. 2015 Sep 15;5:14044. doi: 10.1038/srep14044.

13.

Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.

Olsson B, Cox TF, Psarelli EE, Szamosi J, Hughes AT, Milan AM, Hall AK, Rovensky J, Ranganath LR.

JIMD Rep. 2015;24:21-7. doi: 10.1007/8904_2015_412. Epub 2015 Mar 13.

14.

Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.

Hughes AT, Milan AM, Davison AS, Christensen P, Ross G, Gallagher JA, Dutton JJ, Ranganath LR.

Ann Clin Biochem. 2015 Sep;52(Pt 5):597-605. doi: 10.1177/0004563215571969. Epub 2015 Jan 27.

PMID:
25628464
15.

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.

Ranganath LR, Milan AM, Hughes AT, Dutton JJ, Fitzgerald R, Briggs MC, Bygott H, Psarelli EE, Cox TF, Gallagher JA, Jarvis JC, van Kan C, Hall AK, Laan D, Olsson B, Szamosi J, Rudebeck M, Kullenberg T, Cronlund A, Svensson L, Junestrand C, Ayoob H, Timmis OG, Sireau N, Le Quan Sang KH, Genovese F, Braconi D, Santucci A, Nemethova M, Zatkova A, McCaffrey J, Christensen P, Ross G, Imrich R, Rovensky J.

Ann Rheum Dis. 2016 Feb;75(2):362-7. doi: 10.1136/annrheumdis-2014-206033. Epub 2014 Dec 4.

PMID:
25475116
16.

Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects.

Davison AS, Milan AM, Hughes AT, Dutton JJ, Ranganath LR.

Clin Chem Lab Med. 2015 Feb;53(3):e81-3. doi: 10.1515/cclm-2014-0668. No abstract available.

PMID:
25252754
17.

Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.

Hughes AT, Milan AM, Christensen P, Ross G, Davison AS, Gallagher JA, Dutton JJ, Ranganath LR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 15;963:106-12. doi: 10.1016/j.jchromb.2014.06.002. Epub 2014 Jun 7.

PMID:
24952314
18.

Disruption of daily rhythms in gene expression: the importance of being synchronised.

Hughes AT, Piggins HD.

Bioessays. 2014 Jul;36(7):644-8. doi: 10.1002/bies.201400043. Epub 2014 May 16.

19.

Acute suppressive and long-term phase modulation actions of orexin on the mammalian circadian clock.

Belle MD, Hughes AT, Bechtold DA, Cunningham P, Pierucci M, Burdakov D, Piggins HD.

J Neurosci. 2014 Mar 5;34(10):3607-21. doi: 10.1523/JNEUROSCI.3388-13.2014.

20.

Feedback actions of locomotor activity to the circadian clock.

Hughes AT, Piggins HD.

Prog Brain Res. 2012;199:305-36. doi: 10.1016/B978-0-444-59427-3.00018-6. Review.

PMID:
22877673
21.

Neuropeptide signaling differentially affects phase maintenance and rhythm generation in SCN and extra-SCN circadian oscillators.

Hughes AT, Guilding C, Piggins HD.

PLoS One. 2011 Apr 29;6(4):e18926. doi: 10.1371/journal.pone.0018926.

22.

Rhythm-promoting actions of exercise in mice with deficient neuropeptide signaling.

Power A, Hughes AT, Samuels RE, Piggins HD.

J Biol Rhythms. 2010 Aug;25(4):235-46. doi: 10.1177/0748730410374446.

PMID:
20679493
23.

Circadian oscillators in the epithalamus.

Guilding C, Hughes AT, Piggins HD.

Neuroscience. 2010 Sep 15;169(4):1630-9. doi: 10.1016/j.neuroscience.2010.06.015. Epub 2010 Jun 12.

24.

A riot of rhythms: neuronal and glial circadian oscillators in the mediobasal hypothalamus.

Guilding C, Hughes AT, Brown TM, Namvar S, Piggins HD.

Mol Brain. 2009 Aug 27;2:28. doi: 10.1186/1756-6606-2-28.

25.

Electrophysiological actions of orexins on rat suprachiasmatic neurons in vitro.

Brown TM, Coogan AN, Cutler DJ, Hughes AT, Piggins HD.

Neurosci Lett. 2008 Dec 31;448(3):273-8. doi: 10.1016/j.neulet.2008.10.058. Epub 2008 Nov 1.

PMID:
18973790
26.

Live imaging of altered period1 expression in the suprachiasmatic nuclei of Vipr2-/- mice.

Hughes AT, Guilding C, Lennox L, Samuels RE, McMahon DG, Piggins HD.

J Neurochem. 2008 Aug;106(4):1646-57. doi: 10.1111/j.1471-4159.2008.05520.x. Epub 2008 Jun 28.

27.

Behavioral responses of Vipr2-/- mice to light.

Hughes AT, Piggins HD.

J Biol Rhythms. 2008 Jun;23(3):211-9. doi: 10.1177/0748730408316290.

PMID:
18487413
29.

Aberrant gating of photic input to the suprachiasmatic circadian pacemaker of mice lacking the VPAC2 receptor.

Hughes AT, Fahey B, Cutler DJ, Coogan AN, Piggins HD.

J Neurosci. 2004 Apr 7;24(14):3522-6.

30.
31.

Anti-IgE antibody may help treat some asthma patients.

Hughes AT.

JAMA. 2000 Dec 13;284(22):2859-60. No abstract available.

PMID:
11147975
32.

The use of insulin secretagogues in the treatment of type 2 diabetes.

Luna B, Hughes AT, Feinglos MN.

Prim Care. 1999 Dec;26(4):895-915. Review.

PMID:
10523467
33.

Supplemental Content

Loading ...
Support Center